Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 206

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data

Open access
Grams, Morgan E., Sang, Yingying, Ballew, Shoshana H., Matsushita, Kunihiro, Astor, Brad C., Carrero, Juan Jesus, Chang, Alex R., Inker, Lesley A., Kenealy, Timothy, Kovesdy, Csaba P., Lee, Brian J., Levin, Adeera, Naimark, David, Pena, Michelle J., Schold, Jesse D., Shalev, Varda, Wetzels, Jack F. M., Woodward, Mark, Gansevoort, Ron T., Levey, Andrew S., Coresh, Josef · 2019 · Journal of the American Society of Nephrology

Abstract

Significance Statement: Randomized clinical trials of treatments to slow CKD progression often require large sample sizes and long follow-up to understand their effects on clinical events. This is especially true in patients with earlier stages of kidney disease who are unlikely to experience ESKD for many years. Surrogate study end points that occur earlier during disease progression could help. To evaluate whether eGFR decline over time may be a good surrogate end point, the authors did a meta-analysis of 14 cohorts. They found that slower eGFR decline was significantly associated with lower risk of ESKD in all populations, including those with better kidney function. The results suggest that change in the slope of eGFR decline may be a good surrogate end point for ESKD in clinical trials, particularly in longer trials with patients with rapidly progressive disease. Background: Decline in eGFR is a biologically plausible surrogate end point for the progression of CKD in clinical trials. However, it must first be tested to ensure strong associations with clinical outcomes in diverse populations, including patients with higher eGFR. Methods: To investigate the association between 1-, 2-, and 3-year changes in eGFR (slope) with clinical outcomes over the long term, we conducted a random effects meta-analysis of 3,758,551 participants with baseline eGFR≥60 ml/min per 1.73 m 2 and 122,664 participants with eGFR<60 ml/min per 1.73 m 2 from 14 cohorts followed for an average of 4.2 years. Results: Slower eGFR decline by 0.75 ml/min per 1.73 m 2 per year over 2 years was associated with lower risk of ESKD in participants with baseline eGFR≥60 ml/min per 1.73 m 2 (adjusted hazard ratio, 0.70; 95% CI, 0.68 to 0.72) and eGFR<60 ml/min per 1.73 m 2 (0.71; 95% CI, 0.68 to 0.74). The relationship was stronger with 3-year slope. For a rapidly progressing population with predicted 5-year risk of ESKD of 8.3%, an intervention that reduced eGFR decline by 0.75 ml/min per 1.73 m 2 per year over 2 years would reduce the ESKD risk by 1.6%. For a hypothetical low-risk population with a predicted 5-year ESKD risk of 0.58%, the same intervention would reduce the risk by only 0.13%. Conclusions: Slower decline in eGFR was associated with lower risk of subsequent ESKD, even in participants with eGFR≥60 ml/min per 1.73 m 2, but those with the highest risk would be expected to benefit the most.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2019010008

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 206

Metadata

Authors
Grams, M. E., Sang, Y., Ballew, S. H., Matsushita, K., Astor, B. C., Carrero, J. J., Chang, A. R., Inker, L. A., Kenealy, T., Kovesdy, C. P., Lee, B. J., Levin, A., Naimark, D., Pena, M. J., Schold, J. D., Shalev, V., Wetzels, J. F. M., Woodward, M., Gansevoort, R. T., Levey, A. S., & Coresh, J.
Venue
Journal of the American Society of Nephrology
Published
2019-07-10
Volume
30
Issue
9
Pages
1746-1755
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2960211841
Cited by
206
References
3
FWCI
3.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.